Sartorius Stedim Biotech SA

Sartorius Stedim Biotech SA

247.00
USD
+1.15
(+0.47%)
3.80EPS
64.48P/E
23.71BMarket Cap
Feb 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.39
7.42
9.59
11.41
11.73
13.15
15.63
20.72
31.32
37.9
30.12
28.74
30.5
31.53
Basic EPS, GAAP
0.72
0.79
1.28
1.67
1.75
2.26
2.54
3.64
4.5
9.51
3.37
1.81
2.73
3.34
Free Cash Flow per Basic Share
0.98
0.7
0.97
0.83
0.52
0.55
1.89
2.8
4.1
6.64
2.96
4.91
3.07
4.07
Dividend per Share
0.18
0.2
0.22
0.33
0.42
0.46
0.57
0.34
0.68
1.26
1.44
0.69
0.69
- -
Book Value per Share
4.68
5.78
6.96
8.22
9.46
11.24
12.57
15.6
17.96
26.57
28.63
40.97
42.04
45
Tangible Book Value per Share
0.52
1.14
1.75
2.92
3.4
5.14
5.77
1.53
1.63
4.73
-21.05
-5.68
-3.39
0.01
Basic Weighted Avg Shares
92
92
92
92
92
92
92
92
92
92
92
97
97
97
Sales/Revenue/Turnover
588
684
884
1,052
1,081
1,212
1,441
1,910
2,887
3,493
2,776
2,780
2,968
3,062
Operating Margin (%)
17.92
17.92
22.35
22.99
23.25
23.72
24.2
26.36
30.59
30.21
16.98
14.3
18.18
19.23
Depreciation Expense
31
36
40
45
51
61
73
102
142
182
237
302
318
326
Net Income, GAAP
66
72
118
154
161
208
235
336
414
876
310
175
266
324
Effective Tax Rate (%)
28.56
29.87
29.58
26.81
25.77
26.21
25.64
26.5
35.94
22.16
22.19
18.57
28.75
28.27
Profit Margin (%)
11.26
10.6
13.34
14.61
14.9
17.16
16.28
17.59
14.35
25.08
11.18
6.3
8.95
10.58
Working Capital
103
47
78
147
140
171
208
306
419
635
478
802
29
252
LT Debt
137
33
30
26
62
58
84
563
585
1,112
3,603
2,805
2,019
2,059
Total Equity
482
539
647
764
879
1,045
1,189
1,461
1,733
2,514
2,674
4,024
4,126
4,390
Return on Invested Capital (%)
11.68
12.91
18.04
19.77
16.81
19.28
18.95
19.83
23.88
24.27
6.72
4.45
5.43
- -
Return on Capital (%)
11.2
11.68
16.94
18.97
16.98
18.72
18.75
20.04
19.11
29.52
7.97
4.43
5.36
- -
Return on Common Equity (%)
14.56
14.33
20.1
21.96
19.76
21.8
21.37
25.87
26.79
42.68
12.2
5.29
6.58
- -

Capital Structure

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
606
315
252
LT Borrowings
1,861
1,942
1,915
LT Finance Leases
148
146
144
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
97
97
97
Market Capitalization
16,242
17,033
20,923

Working Capital

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,651
1,353
1,401
Cash, Cash Equivalents & STI
547
233
211
Accounts Receivable, Net
260
273
267
Inventories
715
714
751
Total Current Liabilities
1,609
1,166
1,149
Payables & Accruals
- -
- -
- -
ST Debt
606
315
252
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.17%
24.61%
2.54%
Free Cash Flow
33.54%
18.07%
-37.09%
Net Income, GAAP
19.85%
15.66%
51.68%
Sales/Revenue/Turnover
14.38%
11.7%
6.74%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
667
706
655
751
2,780
2025
745
745
- -
772
2,968
2026
762
766
762
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.58
0.5
0.26
0.47
1.81
2025
0.88
0.7
- -
0.49
2.73
2026
0.91
0.96
0.98
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.69
2025
- -
- -
- -
- -
0.69
2026
- -
- -
- -
- -
- -

Company Description

CEO
René Fáber
Full Time Employees
10,265
Sector
Health technology
Industry
Medical specialties
Address
Zone Industrielle Les Paluds Aubagne PAC France 13781
IPO Date
Oct 20, 1994
Business
Sartorius Stedim Biotech S.A. is a leading global provider of biopharmaceutical and laboratory equipment, specializing in products and services for the development, production, and quality control of biopharmaceuticals. The company’s core offerings include single-use bioreactors; filtration systems; chromatography equipment; fermentation systems; cell culture media and reagents; laboratory balances; and bioanalytical instruments. Sartorius Stedim Biotech serves customers primarily in the biopharmaceutical industry, supporting upstream and downstream processing as well as laboratory applications. Founded in 1870 and headquartered in Aubagne, France, Sartorius Stedim Biotech operates worldwide, providing solutions across Europe, the Americas, and Asia. The company is recognized for its integrated and scalable technologies designed to improve process efficiency and product quality in biopharmaceutical manufacturing. The business comprises multiple segments including bioprocess solutions and lab products and services, targeting biopharmaceutical manufacturers, research institutions, and quality control laboratories. In the last 1-2 years, Sartorius Stedim Biotech has undertaken several strategic initiatives including expanding its product portfolio through acquisitions and partnerships to enhance its single-use technologies. It has launched new bioprocessing products focused on intensified manufacturing processes and increased automation to meet growing industry demands. The company continues to execute global business expansions with an emphasis on integrating digital solutions into bioprocess workflows, furthering its strategic commitment to innovation and sustainability. Sartorius Stedim Biotech operates as a subsidiary within the broader Sartorius Group, which consolidates the company’s efforts in advancing life science research and biopharmaceutical production. This structure supports its focus on delivering high-quality, cutting-edge technologies and services to the rapidly evolving global biopharma market. The company remains committed to strengthening its market position through continuous technological advancements and operational excellence.

Company News

  • Sartorius Stedim Biotech S.A. (SRTOY) Q3 2026 Earnings Call Transcript

  • Baron International Growth Fund Q2 2026 Portfolio Activity

  • Sartorius Stedim Biotech S.A. (SRTOY) Q2 2026 Earnings Call Transcript

  • Sartorius Stedim Biotech S.A. (SRTOY) Q4 2025 Earnings Call Transcript

  • Sartorius Stedim Biotech and Nanotein Technologies Partner to Advance Cell Therapy Manufacturing

  • Bio Usawa Biotechnology and Sartorius Stedim Biotech Forge Partnership to Pioneer Biopharmaceutical Manufacturing in Africa

  • Sartorius Stedim Biotech and Sensible Biotechnologies Partner to Scale Up Sensible's Unique Cell-Based mRNA Design and Manufacturing Platform

  • Sartorius, Sartorius Stedim Biotech shares jump after results beat

  • Sartorius Stedim Biotech S.A. (SDMHF) Q3 2024 Earnings Call Transcript

  • Sartorius Stedim Biotech S.A. (SDMHF) H1 2024 Earnings Call Transcript

  • Sartorius Stedim Biotech S.A. (SDMHF) Q4 2023 Earnings Call Transcript

  • 10 stocks for investors looking for ‘wonderful companies at a fair price'

  • Sartorius Stedim Biotech S.A. (SDMHF) Q3 2023 Earnings Call Transcript

  • Sartorius Stedim Biotech S.A. (SDMHF) Q2 2023 Earnings Call Transcript

  • Sartorius, Sartorius Stedim shares fall after Polyplus acquisition

  • Sartorius Stedim Biotech S.A. (SDMHF) Q4 2022 Earnings Call Transcript